Insulin

The novel prandial insulin formulation from Eli Lilly is now approved for administration via continuous subcutaneous insulin infusion with an insulin pump.

COVID-19 patients with hyperglycemia on hospital admission, with and without diabetes, had increased odds of intubation, ICU admission, and mortality, according to research presented at ENDO 2021.

ENDO 2021: An investigational once-weekly insulin formulation was found as effective as daily basal insulin injection for glucose control with lower rates of hypoglycemia and less weight gain.

Three patients with type 2 diabetes in different stages of life and disease all require insulin management for A1c control.

Insulin degludec vs glargine--which costs less per anum and why? We summarize this study and 2 other direct insulin comparisons reported at ADA 2017.

Stringent control was supported even in patients at high risk for related harm. Reasons found for concern over Rx "deintensification" may surprise you.

Here’s a look at what’s new and interesting on the Web for health care professionals.

Maintaining tight glycemic control in older diabetic adults who are in poor health can do far more harm than good, according to results of a new study.

Activation of opioid receptors with novel approaches may prevent hypoglycemia and lead to safer intensive glycemic control, according to a study reported at the American Diabetes Association 74th Scientific Sessions.

The fact that a "Diabetes Is Primary" session is held in parallel to the ADA scientific sessions is a significant recognition by the American Diabetes Association that primary care providers are the foundation of diabetes care in the United States. Highlights here.

The use of insulin has grown in recent years largely because of the widespread adoption of analogs. Out-of-pocket expenditures per prescription also increased.

Remembering the role the patient can play in preventing medication errors is important. Here I focus on potential errors resulting from nonadherence with insulin.

Patients aged 80 years or older were more than twice as likely to visit the ED and nearly 5 times as likely to be hospitalized for insulin-related hypoglycemia than those aged 45 to 64 years.

Confusion about multiple insulin products; nonadherence to the prescribed regimen; the patient’s injection technique . . . here: a look at why errors occur when insulin is prescribed-and how to prevent them.

GLP-1 receptor antagonists suppress post-meal glucose excursions and are compatible with basal insulin; the combination addresses both FPG and PPG.

Combination therapy that addresses both fasting and post-meal glucose elevation is the next big thing in T2DM management.